DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $39,060,000 | +14.9% | 273,298 | +6.1% | 2.88% | +8.7% |
| Q1 2019 | $33,991,000 | +21.0% | 257,468 | -5.5% | 2.65% | +22.6% |
| Q4 2018 | $28,101,000 | -8.1% | 272,509 | -3.2% | 2.16% | +2.3% |
| Q3 2018 | $30,594,000 | +3.2% | 281,554 | -6.2% | 2.12% | -10.3% |
| Q2 2018 | $29,632,000 | -11.7% | 300,279 | -12.4% | 2.36% | -31.3% |
| Q1 2018 | $33,574,000 | -19.4% | 342,899 | -23.5% | 3.43% | -10.8% |
| Q4 2017 | $41,630,000 | +1.0% | 448,504 | -6.6% | 3.85% | -1.5% |
| Q3 2017 | $41,203,000 | +30.6% | 480,329 | +28.5% | 3.90% | +14.0% |
| Q2 2017 | $31,553,000 | -1.3% | 373,898 | +0.1% | 3.42% | -9.8% |
| Q1 2017 | $31,962,000 | +11.5% | 373,698 | +1.5% | 3.79% | +17.4% |
| Q4 2016 | $28,654,000 | +35.9% | 368,113 | +36.8% | 3.23% | +32.8% |
| Q3 2016 | $21,089,000 | -31.8% | 269,023 | -12.1% | 2.43% | -29.6% |
| Q2 2016 | $30,903,000 | -3.6% | 305,973 | -9.4% | 3.46% | +1.5% |
| Q1 2016 | $32,053,000 | +5.3% | 337,893 | +3.1% | 3.40% | -9.5% |
| Q4 2015 | $30,430,000 | +29.7% | 327,630 | +19.0% | 3.76% | +18.8% |
| Q3 2015 | $23,455,000 | – | 275,260 | – | 3.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |